{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:32:51Z","timestamp":1793831571209,"version":"4.6.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate hyperreflective choroidal foci (HCF) in Sattler\u2019s and Haller\u2019s layers as predictive biomarkers for treatment response and pachychoroid macular atrophy (pMA) development in chronic central serous chorioretinopathy (CSC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Retrospective analysis of 70 treatment-na\u00efve patients with recurrent CSC classified according to Chhablani\u2019s criteria. HCF were quantified separately in choroidal layers using spectral-domain OCT at baseline and 12-month follow-up. Patients received photodynamic therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920), eplerenone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200916), or subthreshold micropulse laser (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934). Primary outcomes included treatment response (complete fluid resolution) and pMA development.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, no significant differences in HCF counts existed between future responders (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200936) and non-responders (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934). At 12 months, responders showed significant HCF reduction in Sattler\u2019s layer (\u22129.17 foci,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001) and Haller\u2019s layer (\u22123.19 foci,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.039), while non-responders demonstrated increased Sattler\u2019s foci (+4.62,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). pMA developed in 15 patients (21.4%), more frequently in non-responders (32.4% vs 11.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Baseline total HCF count was the strongest predictor of pMA development (\u03b2\u2009=\u20090.465,\n                      <jats:italic>R<\/jats:italic>\n                      \u00b2\u2009=\u20090.324,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with final HCF counts showing even stronger associations (\u03b2\u2009=\u20090.512,\n                      <jats:italic>R<\/jats:italic>\n                      \u00b2\u2009=\u20090.348,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Layer-specific HCF quantification provides valuable prognostic information for treatment response and pMA risk in chronic CSC. These biomarkers may guide therapeutic decisions and identify patients requiring closer monitoring for atrophy development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04277-8","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:24:46Z","timestamp":1770276286000},"page":"689-696","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperreflective choroidal foci may predict pachychoroid macular atrophy development in central serous chorioretinopathy"],"prefix":"10.1038","volume":"40","author":[{"given":"Maria Grazia","family":"Pignataro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Chiara","family":"Termite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-899X","authenticated-orcid":false,"given":"Giacomo","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Micelli Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ribezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Carra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-967X","authenticated-orcid":false,"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"4277_CR1","doi-asserted-by":"publisher","unstructured":"Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, et al. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res. 2024. https:\/\/doi.org\/10.1016\/J.PRETEYERES.2024.101236.","DOI":"10.1016\/J.PRETEYERES.2024.101236"},{"key":"4277_CR2","doi-asserted-by":"publisher","first-page":"101372","DOI":"10.1016\/j.preteyeres.2025.101372","volume":"107","author":"P Viggiano","year":"2025","unstructured":"Viggiano P, Boscia G, Sadeghi E, Cheung G, Borrelli E, Alessio G, et al. Pachychoroid disease spectrum: how multimodal imaging and OCT angiography have improved our knowledge. Prog Retin Eye Res. 2025;107:101372. https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101372.","journal-title":"Prog Retin Eye Res"},{"key":"4277_CR3","doi-asserted-by":"publisher","unstructured":"Chhablani J, Cohen FB, Central Serous Chorioretinopathy International Group. Multimodal imaging-based central serous chorioretinopathy classification. Ophthalmol Retin. 2020;4:1043\u20136. https:\/\/doi.org\/10.1016\/j.oret.2020.07.026.","DOI":"10.1016\/j.oret.2020.07.026"},{"key":"4277_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.AJO.2025.04.040","volume":"277","author":"B Ghezzo","year":"2025","unstructured":"Ghezzo B, Ghilardi A, Marena MC, Viggiano P, Boscia F, Serafino S, et al. Postreceptor neural loss in patients with chronic central serous chorioretinopathy. Am J Ophthalmol. 2025;277:26\u201332. https:\/\/doi.org\/10.1016\/J.AJO.2025.04.040.","journal-title":"Am J Ophthalmol"},{"key":"4277_CR5","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/IAE.0000000000003845","volume":"43","author":"E Borrelli","year":"2023","unstructured":"Borrelli E, Barresi C, Battista M, Berni A, Ricardi F, Cascavilla ML, et al. Prevalence and morphologic biomarkers of metamorphopsia in eyes with \u201cresolved\u201d chronic central serous chorioretinopathy. Retina. 2023;43:1563\u201372. https:\/\/doi.org\/10.1097\/IAE.0000000000003845.","journal-title":"Retina"},{"key":"4277_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/J.AJO.2025.04.005","volume":"276","author":"P Viggiano","year":"2025","unstructured":"Viggiano P, Moscara F, Termite AC, Boscia G, La Terza M, Salvelli A, et al. Choroidal layer analysis under flat irregular pigment epithelial detachments in central serous chorioretinopathy. Am J Ophthalmol. 2025;276:210\u20137. https:\/\/doi.org\/10.1016\/J.AJO.2025.04.005.","journal-title":"Am J Ophthalmol"},{"key":"4277_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ajo.2024.01.025","volume":"261","author":"N Imanaga","year":"2024","unstructured":"Imanaga N, Terao N, Wakugawa S, Miyara Y, Sawaguchi S, Oshiro A, et al. Scleral thickness in simple versus complex central serous chorioretinopathy. Am J Ophthalmol. 2024;261:103\u201311. https:\/\/doi.org\/10.1016\/j.ajo.2024.01.025.","journal-title":"Am J Ophthalmol"},{"key":"4277_CR8","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1097\/IAE.0000000000000929","volume":"36","author":"H Lee","year":"2016","unstructured":"Lee H, Lee J, Chung H, Kim HC. Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina. 2016;36:1372\u201380. https:\/\/doi.org\/10.1097\/IAE.0000000000000929.","journal-title":"Retina"},{"key":"4277_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1001\/jamaophthalmol.2014.5604","volume":"133","author":"N Piri","year":"2015","unstructured":"Piri N, Nesmith BLW, Schaal S. Choroidal hyperreflective foci in Stargardt disease shown by spectral-domain optical coherence tomography imaging: correlation with disease severity. JAMA Ophthalmol. 2015;133:398\u2013405. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5604.","journal-title":"JAMA Ophthalmol"},{"key":"4277_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1167\/IOVS.66.6.42","volume":"66","author":"L Ulla","year":"2025","unstructured":"Ulla L, Foti C, Arrigo A, Battaglia Parodi M, Cicinelli MV, Marolo P, et al. Choroidal hyperreflective foci represent a common finding across different types of macular atrophy. Invest Ophthalmol Vis Sci. 2025;66:42. https:\/\/doi.org\/10.1167\/IOVS.66.6.42.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4277_CR11","doi-asserted-by":"publisher","unstructured":"Hasan N, Zarnegar A, Jacob N, Sahoo N, Saju S, Zhou A, et al. Clinical characteristics and progression of pachychoroid macular atrophy in central serous chorioretinopathy. Ophthalmol Retina. 2025. https:\/\/doi.org\/10.1016\/j.oret.2025.04.005.","DOI":"10.1016\/j.oret.2025.04.005"},{"key":"4277_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ajo.2020.10.011","volume":"223","author":"E Borrelli","year":"2021","unstructured":"Borrelli E, Battista M, Sacconi R, Gelormini F, Querques L, Grosso D, et al. OCT Risk factors for 3-year development of macular complications in eyes with \u201cresolved\u201d chronic central serous chorioretinopathy. Am J Ophthalmol. 2021;223:129\u201339. https:\/\/doi.org\/10.1016\/j.ajo.2020.10.011.","journal-title":"Am J Ophthalmol"},{"key":"4277_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100528","volume":"4","author":"Y Sato","year":"2024","unstructured":"Sato Y, Ueda-Arakawa N, Takahashi A, Miyake M, Mori Y, Miyara Y, et al. Clinical characteristics and progression of pachychoroid and conventional geographic atrophy. Ophthalmol Sci. 2024;4. 100528. https:\/\/doi.org\/10.1016\/j.xops.2024.100528.","journal-title":"Ophthalmol Sci"},{"key":"4277_CR14","doi-asserted-by":"publisher","unstructured":"Kim YJ, Sivaprasad S, Aslam T, Mekjavi\u0107 PJ, Bal\u010di\u016bnien\u0117 VJ, Visser L, et al. Treatment of central serous chorioretinopathy: new options for an old disease. Eye. 2025. https:\/\/doi.org\/10.1038\/S41433-025-03894-Z.","DOI":"10.1038\/S41433-025-03894-Z"},{"key":"4277_CR15","doi-asserted-by":"publisher","unstructured":"Toto L, Evangelista F, Viggiano P, Erroi E, D'Onofrio G, Libertini D, et al. Changes in ocular blood flow after ranibizumab intravitreal injection for diabetic macular edema measured using laser speckle flowgraphy. Biomed Res Int. 2020. https:\/\/doi.org\/10.1155\/2020\/9496242.","DOI":"10.1155\/2020\/9496242"},{"key":"4277_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1167\/IOVS.64.14.32","volume":"64","author":"P Viggiano","year":"2023","unstructured":"Viggiano P, Miere A, Borrelli E, Boscia G, Grassi MO, Souied EH, et al. The impact of diabetic retinopathy on the choriocapillaris in neovascular AMD. Invest Ophthalmol Vis Sci. 2023;64:32. https:\/\/doi.org\/10.1167\/IOVS.64.14.32.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4277_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/tvst.8.6.5","volume":"8","author":"E Borrelli","year":"2019","unstructured":"Borrelli E, Costanzo E, Parravano M, Viggiano P, Varano M, Giorno p, et al. Impact of bleaching on photoreceptors in different intermediate AMD phenotypes. Transl Vis Sci Technol. 2019;8:5\u20135. https:\/\/doi.org\/10.1167\/tvst.8.6.5.","journal-title":"Transl Vis Sci Technol"},{"key":"4277_CR18","doi-asserted-by":"publisher","unstructured":"Borrelli E, Toto L, Viggiano P, Evangelista F, Palmieri M, Mastropasqua R. Widefield topographical analysis of the retinal perfusion and neuroretinal thickness in healthy eyes: a pilot study. Eye. 2020. https:\/\/doi.org\/10.1038\/s41433-020-0804-5.","DOI":"10.1038\/s41433-020-0804-5"},{"key":"4277_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3928\/23258160-20191031-11","volume":"50","author":"E Borrelli","year":"2019","unstructured":"Borrelli E, Viggiano P, Evangelista F, Toto L, Mastropasqua R. Eyelashes artifact in ultra-widefield optical coherence tomography angiography. Ophthalmic Surg Lasers Imaging Retin. 2019;50:740\u20133. https:\/\/doi.org\/10.3928\/23258160-20191031-11.","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"key":"4277_CR20","doi-asserted-by":"publisher","unstructured":"Borrelli E, Reibaldi M, Barresi C, Berni A, Introini U, Bandello F. Choroidal hyper-reflective foci in geographic atrophy. Invest Ophthalmol Vis Sci. 2023. https:\/\/doi.org\/10.1167\/IOVS.64.14.5.","DOI":"10.1167\/IOVS.64.14.5"},{"key":"4277_CR21","first-page":"1","volume":"8","author":"J Zhao","year":"2018","unstructured":"Zhao J, Wang YX, Zhang Q, Wei WB, Xu L, Jonas JB. Macular choroidal small-vessel layer, Sattler\u2019s Layer and Haller\u2019s layer thicknesses: the Beijing Eye Study. Sci Rep. 2018;8:1\u201314.","journal-title":"Sci Rep"},{"key":"4277_CR22","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/IAE.0000000000000027","volume":"34","author":"K Fujita","year":"2014","unstructured":"Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Mizota A, et al. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy. Retina. 2014;34:964\u201370. https:\/\/doi.org\/10.1097\/IAE.0000000000000027.","journal-title":"Retina"},{"key":"4277_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1136\/BJOPHTHALMOL-2020-316076","volume":"105","author":"M Ho","year":"2021","unstructured":"Ho M, Lai FHP, Ng DSC, Iu LPL, Chen LJ, Mak ACY, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. Br J Ophthalmol. 2021;105:555\u201360. https:\/\/doi.org\/10.1136\/BJOPHTHALMOL-2020-316076.","journal-title":"Br J Ophthalmol"},{"key":"4277_CR24","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/S40123-023-00816-8","volume":"12","author":"P Viggiano","year":"2023","unstructured":"Viggiano P, Boscia G, Borrelli E, Toto L, Grassi MO, Evangelista F, et al. Choriocapillaris reperfusion in resolved chronic central serous chorioretinopathy treated with eplerenone: long-term effects on the fellow eye. Ophthalmol Ther. 2023;12:3199\u2013210. https:\/\/doi.org\/10.1007\/S40123-023-00816-8.","journal-title":"Ophthalmol Ther"},{"key":"4277_CR25","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.2147\/OPTH.S411094","volume":"17","author":"G Boscia","year":"2023","unstructured":"Boscia G, Viggiano P, Marzulli F, Grassi MO, Puzo P, Dore S, et al. Continuous eplerenone treatment in chronic central serous chorioretinopathy: long-term results from a pilot study. Clin Ophthalmol. 2023;17:2003\u201312. https:\/\/doi.org\/10.2147\/OPTH.S411094.","journal-title":"Clin Ophthalmol"},{"key":"4277_CR26","doi-asserted-by":"publisher","unstructured":"Viggiano P, Boscia G, Borrelli E, Evangelista F, Giancipoli E, Mastropasqua R, et al. Micropulse laser versus eplerenone for chronic central serous chorioretinopathy: a 12-month comparison. Ophthalmol Ther. 2024. https:\/\/doi.org\/10.1007\/S40123-024-01059-X.","DOI":"10.1007\/S40123-024-01059-X"},{"key":"4277_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/JCM14020306","volume":"14","author":"P Viggiano","year":"2025","unstructured":"Viggiano P, Scotti G, Termite AC, Savastano A, Boscia G, Clemente A, et al. Choroidal remodeling after subthreshold micropulse laser in chronic central serous chorioretinopathy: short-term outcomes. J Clin Med. 2025;14:306. https:\/\/doi.org\/10.3390\/JCM14020306.","journal-title":"J Clin Med"},{"key":"4277_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/BJO-2023-323577","volume":"108","author":"SV Sadda","year":"2024","unstructured":"Sadda SV, Sarraf D, Khanani AM, Tadayoni R, Chang AA, Saffar I, et al. Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER. Br J Ophthalmol. 2024;108:852\u20138. https:\/\/doi.org\/10.1136\/BJO-2023-323577.","journal-title":"Br J Ophthalmol"},{"key":"4277_CR29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/J.OPHTHA.2008.12.039","volume":"116","author":"M Bolz","year":"2009","unstructured":"Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116:914\u201320. https:\/\/doi.org\/10.1016\/J.OPHTHA.2008.12.039.","journal-title":"Ophthalmology"},{"key":"4277_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IAE.0B013E318217FFC7","volume":"32","author":"K Ogino","year":"2012","unstructured":"Ogino K, Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012;32:77\u201385. https:\/\/doi.org\/10.1097\/IAE.0B013E318217FFC7.","journal-title":"Retina"},{"key":"4277_CR31","doi-asserted-by":"publisher","unstructured":"Cheung CMG, Dansingani KK, Koizumi H, Lai TYY, Sivaprasad S, Boon CJF, et al. Pachychoroid disease: review and update. Eye. 2024. https:\/\/doi.org\/10.1038\/s41433-024-03253-4.","DOI":"10.1038\/s41433-024-03253-4"},{"key":"4277_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-42052-w","volume":"9","author":"J Baek","year":"2019","unstructured":"Baek J, Kook L, Lee WK. Choriocapillaris flow impairments in association with pachyvessel in early stages of pachychoroid. Sci Rep. 2019;9:1\u20136.","journal-title":"Sci Rep"},{"key":"4277_CR33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.5301\/EJO.5000796","volume":"27","author":"J Ruiz-Medrano","year":"2017","unstructured":"Ruiz-Medrano J, Pellegrini M, Cereda MG, Cigada M, Staurenghi G. Choroidal characteristics of acute and chronic central serous chorioretinopathy using enhanced depth imaging optical coherence tomography. Eur J Ophthalmol. 2017;27:476\u201380. https:\/\/doi.org\/10.5301\/EJO.5000796.","journal-title":"Eur J Ophthalmol"},{"key":"4277_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ajo.2024.06.023","volume":"267","author":"A Berni","year":"2024","unstructured":"Berni A, Shen M, Cheng Y, Herrera G, Hiya F, Liu J, et al. The total macular burden of hyperreflective foci and the onset of persistent choroidal hypertransmission defects in intermediate AMD. Am J Ophthalmol. 2024;267:61\u201375. https:\/\/doi.org\/10.1016\/j.ajo.2024.06.023.","journal-title":"Am J Ophthalmol"},{"key":"4277_CR35","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/J.OPHTHA.2012.10.018","volume":"120","author":"JG Christenbury","year":"2013","unstructured":"Christenbury JG, Folgar FA, O\u2019Connell RV, Chiu SJ, Farsiu S, Toth CA. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013;120:1038\u201345. https:\/\/doi.org\/10.1016\/J.OPHTHA.2012.10.018.","journal-title":"Ophthalmology"},{"key":"4277_CR36","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/S00417-019-04546-1","volume":"258","author":"Y Hsia","year":"2020","unstructured":"Hsia Y, Yang CH, Hsieh YT, Yang CM, Ho TC, Lai TT. Hyperreflective foci in predicting the treatment outcome of antivascular endothelial growth factor in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2020;258:273\u201380. https:\/\/doi.org\/10.1007\/S00417-019-04546-1.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04277-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04277-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:38:36Z","timestamp":1774352316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04277-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4277"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04277-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EB is a member of the Eye editorial board. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}